Atropine and Pralidoxime Chloride, 'Duodote Kit"

The Department of Health and Human Services Office of the Assistant Secretary for Administration is seeking to procure Atropine and Pralidoxime Chloride, commonly known as "Duodote Kit," which is a pharmaceutical treatment for nerve agent or insecticide exposure. This pre-solicitation notice indicates that the agency will issue a formal solicitation by November 18, 2025, providing potential vendors with advance notice to prepare their proposals. The procurement falls under the Pharmaceutical Preparation Manufacturing NAICS category (325412) and the Drugs and Biologicals PSC category (6505), indicating this is a specialized pharmaceutical acquisition. While specific evaluation criteria have not been detailed in this pre-solicitation notice, vendors should be prepared to demonstrate their capability to supply pharmaceutical products that meet federal quality and regulatory standards. Interested parties should monitor the Federal Procurement Data System for the formal solicitation release, which is expected shortly after this pre-solicitation posting date of November 4, 2025.

This procurement carries no set-aside designations, meaning it is open to all eligible vendors without restrictions for small businesses, veteran-owned enterprises, or other protected categories. The federal government requires a total of 5,130 Duodote Kits, comprising 171 boxes with 30 kits per box, with the specification referencing NDC 11704-0620-01 or an equivalent product. No specific contract value or budget range has been disclosed in this pre-solicitation notice, though the quantity ordered suggests a substantial procurement. The lack of incumbent contractor information in this notice indicates this may be a new procurement or a re-compete of a previous contract. Vendors should prepare comprehensive proposals addressing product specifications, delivery capabilities, pricing, and compliance with federal pharmaceutical regulations in anticipation of the formal solicitation deadline.